The correlation between PTEN-loss and immunotherapy resistance has been also confirmed by evaluating PTEN expression in patients with metastatic melanoma treated with anti–PD-1 antibodies: PTEN expression is generally related to a greater reduction of tumor size in respect to PTEN-negative tumors (40). The gene discussed is PTEN; the disease is metastatic melanoma.